Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer

J Chemother. 1989 Oct;1(5):350-1. doi: 10.1080/1120009x.1989.11738921.

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated with high-dose folinic acid (HDFA): 200 mg/m2 i.v. and 5-fluorouracil (5-FU): 370 mg/m2 i.v. for 5 consecutive days every 28 days. Severe oral mucositis (WHO grade III-IV) was experienced by two patients, whereas hematological toxicity was mild. No complete or partial remission was observed. Short-lasting stable disease occurred in 8 patients (median = 5 months, range 2-11). This combination does not need further evaluation in patients with RCC.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Leucovorin / administration & dosage
  • Male
  • Middle Aged

Substances

  • Leucovorin
  • Fluorouracil